TABLE 5.
Pharmacokinetics of rosuvastatin in individuals with different SLCO2B1 c.1457C > T genotypes
| Variable | SLCO2B1 c.1457C/T (n = 18) | SLCO2B1 c.1457C/C (n = 229) | |
|---|---|---|---|
| Mean (90% CI) | Ratio to c.1457C/C (90% CI); P‐value | Mean (90% CI) | |
| C max (ng/mL) | 13.9 (11.1–17.4) | 0.67 (0.52–0.86); P = .0080 | 20.7 (18.7–23.0) |
| AUC0‐∞ (ng × h/mL) | 128.3 (105.7–155.7) | 0.72 (0.58–0.89); P = .011 | 178.6 (163.6–195.1) |
| t ½ (h) | 13.4 (11.4–15.8) | 1.29 (1.08–1.54); P = .022 | 10.4 (9.7–11.2) |
Data are estimated marginal means adjusted for weight (AUC0‐∞ and C max), SLCO1B1 genotype‐predicted OATP1B1 function and ABCG2 c.421C > A genotype. None of the study participants was homozygous for the SLCO2B1 c.1457C > T variant. AUC0–∞, area under the plasma concentration–time curve from zero to infinity; CI, confidence interval; C max, peak plasma concentration; t ½, elimination half‐life.